|

Anlotinib hydrochloride Clinical Trials

3 actively recruiting trials

No change since May 2026

Also known as: FuKeWei, SRT

Pipeline

Phase 2: 2

Top Sponsors

  • The First People's Hospital of Lianyungang1
  • Jiangxi Provincial Cancer Hospital1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer3
  • Neoplasms, Squamous Cell1
  • Major Wound Complications1
  • Trunk1
  • Extremity1

Other3 trials

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
Phase 2
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）
Phase 2
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.